Standard BioTools shares surge 20.22% intraday after exceeding 2025 revenue guidance and announcing SomaLogic sale to Illumina.

Standard BioTools (NASDAQ: LAB) surged 20.22% intraday after announcing preliminary 2025 revenue of $185 million for combined operations and $85 million from continuing operations, exceeding guidance. The company highlighted exceeding expectations amid cost-optimization efforts and a path toward positive adjusted EBITDA. CEO Michael Egholm emphasized strategic improvements, including a streamlined operating model and $550 million in anticipated cash from the pending SomaLogic sale to Illumina, scheduled for H1 2026. These developments, coupled with strong full-year execution, underscored the stock’s sharp intraday rally as investors reacted favorably to the revenue outperformance and enhanced strategic flexibility.